drugset
drugset / Trial / NCT01159418

LBH589 Oral in Combination With Carboplatin and Paclitaxel in Advanced Solid Tumors

NCT01159418 ↗

Phase 1 Unknown 36 enrolled Southern Europe New Drug Organization Novartis · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the Maximum Tolerated Dose (MTD) of Panobinostat (LBH589) when administered in combination with Carboplatin and Paclitaxel in patients with advanced solid malignancies and to identify the Recommended Dose (RD) for a subsequent Phase II study.

Timeline

Start
2008-06
Primary completion
2011-12
Completion
2012-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Paclitaxel Small molecule 135 mg/m2 —
Subject Paclitaxel Small molecule 175 mg/m2 —
Subject Panobinostat Small molecule 20 mg Oral
Subject Panobinostat Small molecule 30 mg Oral
Subject Panobinostat Small molecule 45 mg Oral
Background Carboplatin Small molecule — Intravenous

Indications

neoplasm